Respirable antisense oligonucleotides: a new drug class for respiratory disease

• Published in: Respiratory research Vol. 2; no. 1; pp. 5 - 9
• Main Authors: Tanaka, M, Nyce, J W
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 01.01.2001; BioMed Central; BMC
• Subjects: Administration, Inhalation; Animals; Anti-Asthmatic Agents - therapeutic use; asthma; Disease Models, Animal; DNA medicines; Humans; Oligonucleotides, Antisense - administration & dosage; Oligonucleotides, Antisense - therapeutic use; Phosphates - therapeutic use; Primates; Respiration Disorders - drug therapy; respiratory disease; Review
• ISSN: 1465-9921; 1465-993X; 1465-993X
• DOI: 10.1186/rr32

Respirable antisense oligonucleotides (RASONs), which attenuate specific disease-associated mRNAs, represent a new class of respiratory therapeutics with considerable potential. RASONs overcome previous obstacles that have impeded the development of antisense therapeutics targeting diseases in other organ systems. RASONs are delivered directly to the target tissue via inhalation; their uptake seems to be enhanced by cationic properties inherent in pulmonary surfactant, and, because of the markedly different target properties of mRNA and proteins, they can have very long durations of effect compared with traditional drugs targeting the protein of the same gene. RASONs contain chemical modifications that decrease their degradation by cellular nucleases. However, total insensitivity to nucleases is probably not an optimal design criterion for RASONs, because moderate nuclease sensitivity can prevent their systemic delivery, decreasing the potential for systemic toxicity. EPI-2010 is a 21-mer phosphorothioate RASON that attenuates bronchoconstriction, inflammation and surfactant depletion in preclinical models of human asthma, has a duration of effect of seven days, and seems to undergo minimal systemic delivery.